Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-02-04
2010-06-22
Navarro, Mark (Department: 1645)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S184100
Reexamination Certificate
active
07741297
ABSTRACT:
Covalently lipidated oligonucleotides comprising the CpG dinucleotide unit, or an analogue thereof, may be used as immunostimulatory agents to protect against a disease caused by a cancer cell or a pathogen, either alone or in conjunction with immunogens and/or non-immunological agents.Lipidated oligonucleotides with special backbones, lipidated oligonucleotides with fewer than eight nucleotides, and lipidated oligonucleotides comprising a plurality of CpG dinucleotide-containing segments connected by a long internucleoside linkage are of particular interest. These compounds are also novel per se.
REFERENCES:
patent: 4235871 (1980-11-01), Papahadjopoulos et al.
patent: 4501728 (1985-02-01), Geho et al.
patent: 4837028 (1989-06-01), Allen
patent: 4894229 (1990-01-01), Polson et al.
patent: 5019369 (1991-05-01), Presant et al.
patent: 5223263 (1993-06-01), Hostetler
patent: 5416203 (1995-05-01), Letsinger
patent: 5646126 (1997-07-01), Cheng et al.
patent: 5677439 (1997-10-01), Weis et al.
patent: 5717083 (1998-02-01), Cook et al.
patent: 5744144 (1998-04-01), Finn et al.
patent: 5750669 (1998-05-01), Rösch et al.
patent: 5756352 (1998-05-01), Sridhar et al.
patent: 5827831 (1998-10-01), Hostetler et al.
patent: 5856462 (1999-01-01), Agrawal
patent: 6013779 (2000-01-01), Wong et al.
patent: 6086898 (2000-07-01), DeKruyff et al.
patent: 6111085 (2000-08-01), Cook et al.
patent: 6114513 (2000-09-01), Cook et al.
patent: 6300319 (2001-10-01), Manoharan
patent: 6344203 (2002-02-01), Sandrin et al.
patent: 10 251292 (1998-12-01), None
patent: WO 98/18810 (1998-05-01), None
patent: WO 98/40100 (1998-09-01), None
patent: WO 99/51259 (1999-10-01), None
patent: WO 99/61056 (1999-12-01), None
patent: WO 00/54803 (2000-09-01), None
patent: WO 01/07055 (2001-02-01), None
patent: WO 01/12804 (2001-02-01), None
patent: WO 01/83503 (2001-11-01), None
patent: WO 01/97843 (2001-12-01), None
Alexopoulou, et al., “Recognition of double-stranded RNA and activation of NF-kB by Toll-like receptor 3”,Nature, vol. 413, pp. 732-738, Oct. 18, 2001.
Davis, et al., “Drug Leads from Combinatorial Phosphodiester Libraries”,Med. Chem., vol. 38, pp. 4363-4366, 1995.
Hemmi, et al., “A Toll-like receptor recognizes bacterial DNA”,Nature, vol. 408, pp. 740-745, Dec. 7, 2000.
Hiltbold, et al., “Naturally Processed Class II Epitope from the Tumor Antigen MUC1 Primes Human CD4+T Cells”,Cancer Research, vol. 58, pp. 5066-5070, Nov. 15, 1998.
Kabanov, et al., “A new class of antivirals: antisense oligonucleotides combined with a hydrophobic substituent effectively inhibit influenza virus reproduction and synthesis of virus-specific proteins in MDCK cells”,FEBS Letters, vol. 259, No. 2, pp. 327-330, Jan. 1990.
Krieg, et al., “CpG motifs in bacterial DNA trigger direct B-cell activation”,Nature, vol. 374, pp. 546-549, Apr. 6, 1995.
Matysiak, et al., “Acetall Oligonucleotide Conjugates In Antisense Strategy”,Nucleosides&Nucleotides, vol. 16, pp. 855-861, 1997.
Mensdorff-Pouilly, et al., “Human MUC1 mucin: a multifaceted glycoprotein”,The International Journal of Biological Markers, vol. 15, No. 4, pp. 343-356, 2000.
Mensdorff-Pouilly, et al., “Reactivity of Natural and Induced Human Antibodies To MUC1 Mucin with MUC1 Peptides andN-Acetylgalactosamine (GalNAc) Peptides”,Int. J. Cancer, vol. 86, pp. 702-712, 2000.
Mensdorff-Pouilly, et al., “Survival in Early Breast Cancer Patients is Favorably Influenced by a Natural Humoral Immune Response to Polymorphic Epithelial Mucin”,Journal of Clinical Oncology, vol. 18, No. 3, pp. 574-583, Feb. 2000.
Meylan, et al., “Atom/Fragment Contribution Method for Estimating Octanol-Water Partition Coefficients”,Journal of Pharmaceutical Sciences, vol. 84, No. 1, pp. 83-92, Jan. 1995.
Möller, et al., “NMR-based determination of the binding epitope and conformational analysis of MUC-1 glycopeptides and peptides bound to the breast cancer-selective monoclonal antibody SM3”,Eur. J. Biochem., vol. 269, pp. 1444-1455, 2002.
Ragupathi, et al., “Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl) cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cells”,Cancer Immunol. Immunother., vol. 48, pp. 1-8, 1999.
Reddish, et al., “Specificities of anti-sialyl-Tn and anti-Tn monoclonal antibodies generated using novel clustered synthetic glycopeptide epitopes”,Glycoconjugate Journal, vol. 14, pp. 549-560, 1997.
Schneider, et al., “Oligonucleotides Containing Flexible Nucleoside Analogues”,J. Am. Chem. Soc., vol. 112, pp. 453-455, 1990.
Schreiber, et al., “Binding of Tumor Antigen Mucin (MUC1) Derived Peptides to the Heat Shock Protein DnaK”,Anticancer Research, vol. 20, pp. 3093-3098, 2000.
Shea, et al. “Synthesis, hybridization properties and antiviral activity of lipid-oligodeoxynucleotide conjugates”,Nucleic Acids Research, vol. 18, No. 13, pp. 3777-3783, 1990.
Soares, et al., “Three Different Vaccines Based on the 140-Amino Acid MUC1 Peptide with Seven Tandemly Repeated Tumor-Specific Epitopes Elicit Distinct Immune Effector Mechanisms in Wild-Type Versus MUC1-Transgenic Mice with Different Potential for Tumor Rejection”,The Journal of Immunology, vol. 166, pp. 6555-6563, 2001.
Sonehara, et al., “Hexamer Palindromic Oligonucleotides with 5′-CG-3′ Motif(s) Induce Production of Interferon”,Journal of Interferon and Cytokine Research, vol. 16, pp. 799-803, 1996.
Takeuchi, et al., “Differential Roles of TLR2 and TLR4 in Recognition of Gram-Negative and Gram-Positive Bacterial Cell Wall Components”,Immunity, vol. 11, pp. 443-451, Oct. 1999.
Uhlmann, et al., “Antisense Oligonucleotides: A New Therapeutic Principle”,Chemical Reviews, vol. 90, No. 4, pp. 544-584, Jun. 1990.
Uhlmann, et al., “PNA: Synthetic Polyamide Nucleic Acids with Unusual Binding Properties”,Angew. Chem. Int. Ed., vol. 37, pp. 2797-2823, 1998.
Usman, et al., “Preparation of Glyceronucleoside Phosphoramidite Synthons and Their Use In The solid Phase Synthesis of Acyclic Oligonucleotides”,Tetrahedron Letters, vol. 29, No. 38, pp. 4831-4834, 1988.
Baek Myung-Gi
Jiang Zi-Hua
Koganty Rao
Yalamati Damayanthi
Cooper Iver P.
Navarro Mark
Oncothyreon Inc.
LandOfFree
Immunostimulatory, covalently lipidated oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunostimulatory, covalently lipidated oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunostimulatory, covalently lipidated oligonucleotides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4165246